Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Liver Transplantation 4Gemcitabine 4Cisplatin 4Capecitabine 4Radiosurgery 3toripalimab 2Specimen Handling 2Self Expandable Metallic Stents 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2trisacryl gelatin microspheres 1tremelimumab 1tislelizumab 1temoporfin 1sacituzumab govitecan 1ricolinostat 1pembrolizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1fludarabine 1durvalumab 1Saline Solution 1Radiofrequency Ablation 1Photosensitizing Agents 1Photochemotherapy 1Pancreatic Hormones 1Optical Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Klatskin Tumor × ricolinostat × Clear all
NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡